Ayman Megally

678 total citations · 2 hit papers
15 papers, 425 citations indexed

About

Ayman Megally is a scholar working on Physiology, Immunology and Allergy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ayman Megally has authored 15 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 8 papers in Immunology and Allergy and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ayman Megally's work include Asthma and respiratory diseases (14 papers), Allergic Rhinitis and Sensitization (8 papers) and Respiratory and Cough-Related Research (3 papers). Ayman Megally is often cited by papers focused on Asthma and respiratory diseases (14 papers), Allergic Rhinitis and Sensitization (8 papers) and Respiratory and Cough-Related Research (3 papers). Ayman Megally collaborates with scholars based in United States, United Kingdom and Spain. Ayman Megally's co-authors include Gene Colice, Christopher E. Brightling, Claire Emson, Sarah Diver, Jane R. Parnes, Andrew Menzies‐Gow, Sally E. Wenzel, Néstor A. Molfino, Michael E. Wechsler and James Johnston and has published in prestigious journals such as New England Journal of Medicine, Journal of Allergy and Clinical Immunology and Clinical & Experimental Immunology.

In The Last Decade

Ayman Megally

12 papers receiving 419 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

2021 225 citations Sarah Diver, Latifa Khalfaoui et al. The Lancet Respiratory Medicine profile →
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps

2025 35 citations Joseph K. Han, Martin Desrosiers et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ayman Megally United States	8	361	179	161	112	62	15	425
О М Курбачева Russia	10	169 0.5×	63 0.4×	162 1.0×	59 0.5×	40 0.6×	106	311
S. Pollard United States	6	453 1.3×	306 1.7×	247 1.5×	45 0.4×	32 0.5×	10	481
Marcello Cottini Italy	12	309 0.9×	293 1.6×	47 0.3×	35 0.3×	10 0.2×	29	426
Nkiruka Erekosima United States	7	411 1.1×	82 0.5×	432 2.7×	28 0.3×	238 3.8×	7	500
Chris RuiWen Kuo United Kingdom	9	219 0.6×	172 1.0×	70 0.4×	24 0.2×	5 0.1×	27	272
Agamemnon Bakakos Greece	7	134 0.4×	96 0.5×	32 0.2×	45 0.4×	3 0.0×	21	182
Krishna Pancham United States	7	53 0.1×	94 0.5×	20 0.1×	39 0.3×	9 0.1×	10	200
Kazuyuki Kurihara Japan	6	133 0.4×	57 0.3×	155 1.0×	13 0.1×	30 0.5×	27	235
Michaela Barnikel Germany	8	91 0.3×	118 0.7×	40 0.2×	24 0.2×	3 0.0×	19	198
Jérémy Charriot France	8	109 0.3×	115 0.6×	29 0.2×	25 0.2×	5 0.1×	25	195

Countries citing papers authored by Ayman Megally

Since Specialization

Citations

This map shows the geographic impact of Ayman Megally's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayman Megally with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayman Megally more than expected).

Fields of papers citing papers by Ayman Megally

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayman Megally. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayman Megally. The network helps show where Ayman Megally may publish in the future.

Co-authorship network of co-authors of Ayman Megally

This figure shows the co-authorship network connecting the top 25 collaborators of Ayman Megally. A scholar is included among the top collaborators of Ayman Megally based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayman Megally. Ayman Megally is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Movitz, Charlotta, et al.. (2026). Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. The Lancet Respiratory Medicine.

Han, Joseph K., Martin Desrosiers, Claire Hopkins, et al.. (2025). Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. New England Journal of Medicine. 392(12). 1178–1188. 35 indexed citations breakdown →

Peters, Anju T., Joseph K. Han, Enrico Heffler, et al.. (2025). Thymic stromal lymphopoietin as a therapeutic target in patients with chronic rhinosinusitis and nasal polyps. Clinical & Experimental Immunology. 219(1).

Muro, Shigeo, Tomotaka Kawayama, Hisatoshi Sugiura, et al.. (2024). Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history. Respiratory Research. 25(1). 297–297. 1 indexed citations

Muro, Shigeo, John R. Hurst, Jonathan Marshall, et al.. (2024). Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS. International Journal of COPD. Volume 19. 2729–2737.

Peters, Anju T., et al.. (2024). Efficacy of Biologics in Patients With Moderate-to-Severe, Uncontrolled Asthma and Nasal Polyps. Journal of Allergy and Clinical Immunology. 153(2). AB100–AB100. 2 indexed citations

Nordenmark, Lars H., Åsa Hellqvist, Claire Emson, et al.. (2023). Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma. NEJM Evidence. 2(10). EVIDoa2300135–EVIDoa2300135. 53 indexed citations

Laidlaw, Tanya M., Andrew Menzies‐Gow, Joseph K. Han, et al.. (2023). Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. Journal of Asthma and Allergy. Volume 16. 915–932. 30 indexed citations

Brightling, Christopher E., Paul M. O’Byrne, Celeste Porsbjerg, et al.. (2023). Effect of Tezepelumab on Airway Hyperresponsiveness by Baseline Blood Eosinophil Count in Patients With Severe, Uncontrolled Asthma in the Phase 2 CASCADE Study. A4750–A4750. 1 indexed citations

10.

Alpizar, Sady, et al.. (2021). Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma. Journal of Asthma and Allergy. Volume 14. 381–392. 18 indexed citations

11.

Diver, Sarah, Latifa Khalfaoui, Claire Emson, et al.. (2021). Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 9(11). 1299–1312. 225 indexed citations breakdown →

12.

Diver, Sarah, Latifa Khalfaoui, Claire Emson, et al.. (2021). Effect of Tezepelumab on Airway Inflammation in Patients with Moderate-to-Severe Uncontrolled Asthma: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study (CASCADE). A1456–A1456. 1 indexed citations

13.

Emson, Claire, Sarah Diver, Latifa Chachi, et al.. (2020). CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. Respiratory Research. 21(1). 265–265. 25 indexed citations

14.

Zheng, Yanan, Lubna Abuqayyas, Ayman Megally, et al.. (2020). Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers. Clinical Therapeutics. 43(1). 142–155.e5. 21 indexed citations

15.

Carlsson, Mats, Martin Braddock, Yuling Li, et al.. (2019). Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. Drug Safety. 42(6). 769–784. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact